Extensive-stage Small-cell Lung Cancer Clinical Trials

23 recruitingLast updated: June 17, 2026

There are 23 actively recruiting extensive-stage small-cell lung cancer clinical trials across 32 countries. Studies span Phase 2, Phase 1, Phase 3, Not Applicable, Phase 4. Top locations include Shanghai, Shanghai Municipality, China, Chicago, Illinois, United States, Los Angeles, California, United States. Updated daily from ClinicalTrials.gov.


Extensive-stage Small-cell Lung Cancer Trials at a Glance

23 actively recruiting trials for extensive-stage small-cell lung cancer are listed on ClinicalTrialsFinder across 6 cities in 32 countries. The largest study group is Phase 2 with 13 trials, with the heaviest enrollment activity in Shanghai, Chicago, and Los Angeles. Lead sponsors running extensive-stage small-cell lung cancer studies include Amgen, Henan Cancer Hospital, and Sichuan University.

Browse extensive-stage small-cell lung cancer trials by phase

Treatments under study

About Extensive-stage Small-cell Lung Cancer Clinical Trials

Looking for clinical trials for Extensive-stage Small-cell Lung Cancer? There are currently 23 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Extensive-stage Small-cell Lung Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Extensive-stage Small-cell Lung Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 23 trials

Recruiting
Phase 3

A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

Extensive-stage Small-cell Lung Cancer
Bristol-Myers Squibb530 enrolled183 locationsNCT06646276
Recruiting
Phase 3

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

Small Cell Lung CancerExtensive-stage Small-cell Lung Cancer
Amgen330 enrolled158 locationsNCT07005128
Recruiting
Phase 2

Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer

Extensive-stage Small-cell Lung Cancer
Muhammad Furqan30 enrolled5 locationsNCT04699838
Recruiting
Phase 1

A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer

Extensive-stage Small-cell Lung Cancer
Memorial Sloan Kettering Cancer Center24 enrolled7 locationsNCT06807632
Recruiting
Phase 2

Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC

Extensive-stage Small-cell Lung Cancer
Guangzhou Institute of Respiratory Disease30 enrolled1 locationNCT06497530
Recruiting
Phase 3

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

Extensive-stage Small-cell Lung Cancer
BioNTech SE621 enrolled202 locationsNCT06712355
Recruiting
Phase 1

A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)

Extensive-stage Small-cell Lung Cancer
Amgen380 enrolled19 locationsNCT07037758
Recruiting
Phase 1

Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)

Extensive-stage Small-cell Lung Cancer
Amgen220 enrolled31 locationsNCT06598306
Recruiting
Phase 1Phase 2

Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC

Lung CancerExtensive-stage Small-cell Lung Cancer
Sichuan University45 enrolled1 locationNCT06217757
Recruiting
Phase 2

MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer

SCLCSmall Cell Lung CancerLimited Stage Small Cell Lung Cancer+1 more
Hirva Mamdani84 enrolled4 locationsNCT05903092
Recruiting
Phase 2

Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC

Extensive-stage Small-cell Lung Cancer
Second Hospital of Shanxi Medical University40 enrolled6 locationsNCT06536868
Recruiting
Phase 2

Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)

Lung CancerSmall Cell Lung CancerExtensive-stage Small-cell Lung Cancer
University of Chicago49 enrolled2 locationsNCT05068232
Recruiting
Phase 1

A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER

Extensive-stage Small-cell Lung Cancer
Chugai Pharmaceutical122 enrolled6 locationsNCT07107490
Recruiting
Phase 1Phase 2

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

Extensive-stage Small-cell Lung Cancer
Daiichi Sankyo123 enrolled58 locationsNCT06362252
Recruiting

Clinical Study on Using TCR to Predict the Effect of Tislelizumab + Chemotherapy in the First-line Treatment of ES-SCLC

Extensive-stage Small-cell Lung Cancer
Henan Cancer Hospital40 enrolled1 locationNCT07244016
Recruiting
Phase 2

Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases

Liver MetastasesExtensive-stage Small-cell Lung Cancer
Kamya Sankar39 enrolled3 locationsNCT05588388
Recruiting
Phase 4

Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan

Extensive-stage Small-cell Lung Cancer
Pharmacosmos A/S302 enrolled1 locationNCT05874401
Recruiting
Phase 2

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer

Extensive-stage Small-cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.66 enrolled1 locationNCT06437509
Recruiting
Phase 2

First-line Treatment for ES-SCLC with Chemotherapy Combined with PD-1/PD-L1 Inhibitor Sequential Thoracic Radiotherapy

Extensive-stage Small-cell Lung Cancer
Henan Cancer Hospital47 enrolled1 locationNCT06586697
Recruiting
Phase 1Phase 2

Radiotherapy to All Residual Lesions After Chemoimmunotherapy

Extensive-stage Small-cell Lung Cancer
Anhui Provincial Hospital150 enrolled1 locationNCT06479473